Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path

uniQure (QURE) saw a 6.4% stock increase after the FDA agreed to an accelerated approval path for its Huntington’s disease gene therapy, AMT-130. Despite a recent wider net loss and reliance on AMT-130's success, the company secured a $259 million capital raise to support its confirmatory trial and potential commercialization. The accelerated approval framework provides clearer next steps but also highlights the significant capital commitment required for the multi-year project.